CytoMed Therapeutics Ltd
Company Profile
Business description
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
Contact
1 Commonwealth Lane
No. 08-22 One Commonwealth
Singapore149544
SGPT: +65 62507738
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
42
Stocks News & Analysis
stocks
An undervalued stock to buy that even Warren Buffett likes
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,841.20 | 55.80 | -0.63% |
| CAC 40 | 8,081.43 | 41.98 | -0.52% |
| DAX 40 | 25,266.53 | 144.10 | -0.57% |
| Dow JONES (US) | 51,349.98 | 161.61 | -0.31% |
| FTSE 100 | 10,679.99 | 25.27 | -0.24% |
| HKSE | 24,333.52 | 427.61 | -1.73% |
| NASDAQ | 26,939.37 | 3.34 | 0.01% |
| Nikkei 225 | 66,318.14 | 804.15 | 1.23% |
| NZX 50 Index | 13,805.35 | 19.48 | -0.14% |
| S&P 500 | 7,704.13 | 1.90 | -0.02% |
| S&P/ASX 200 | 8,658.10 | 43.90 | -0.50% |
| SSE Composite Index | 3,888.37 | 48.15 | -1.22% |